Allogeneic transplantation of haematopoietic progenitors for myelodysplastic syndromes and myeloproliferative disorders

Research output: Contribution to journalArticle

Abstract

Since children with myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) have a poor prognosis and conventional chemotherapy did not prove to be effective in eradicating them, paediatric patients affected by these diseases and with an HLA-histocompatible donor are to be considered elective candidates for allogeneic transplantation of haematopoietic stem cells (HSC). For those patients with a compatible sibling relapse remains the most important problem, whereas in children rejection and transplant-related mortality significantly contribute to treatment failure. A detailed analysis on the different patient, disease and treatment factors correlated with transplant outcome in childhood MDS and MPD is discussed.

Original languageEnglish
JournalBone Marrow Transplantation
Volume21
Issue numberSUPPL. 2
Publication statusPublished - Apr 1998

Keywords

  • Allogeneic transplantation of haematopoietic stem cells
  • Chronic myeloid leukemia
  • Myelodysplastic syndromes
  • Pediatric haematology

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic transplantation of haematopoietic progenitors for myelodysplastic syndromes and myeloproliferative disorders'. Together they form a unique fingerprint.

  • Cite this